Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Down 16.9% in April

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) saw a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 2,070,000 shares, a decrease of 16.9% from the March 31st total of 2,490,000 shares. Based on an average trading volume of 2,290,000 shares, the days-to-cover ratio is presently 0.9 days. Currently, 3.8% of the shares of the company are sold short.

Vanda Pharmaceuticals Price Performance

Shares of VNDA stock opened at $4.62 on Friday. The stock has a market cap of $265.83 million, a P/E ratio of 92.42 and a beta of 0.76. Vanda Pharmaceuticals has a one year low of $3.30 and a one year high of $7.00. The stock has a fifty day moving average price of $4.27 and a 200 day moving average price of $4.07.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.05. The firm had revenue of $45.27 million during the quarter, compared to analysts’ expectations of $37.00 million. Vanda Pharmaceuticals had a return on equity of 0.46% and a net margin of 1.30%. Equities research analysts anticipate that Vanda Pharmaceuticals will post -0.06 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on VNDA. TheStreet cut Vanda Pharmaceuticals from a “c-” rating to a “d” rating in a research report on Thursday, February 8th. StockNews.com cut Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, April 22nd.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Acadian Asset Management LLC raised its stake in Vanda Pharmaceuticals by 53.7% during the third quarter. Acadian Asset Management LLC now owns 1,750,655 shares of the biopharmaceutical company’s stock worth $7,559,000 after acquiring an additional 611,564 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its stake in Vanda Pharmaceuticals by 19.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 965,856 shares of the biopharmaceutical company’s stock worth $4,172,000 after acquiring an additional 156,896 shares in the last quarter. GSA Capital Partners LLP raised its stake in Vanda Pharmaceuticals by 39.8% during the fourth quarter. GSA Capital Partners LLP now owns 567,756 shares of the biopharmaceutical company’s stock worth $2,396,000 after acquiring an additional 161,737 shares in the last quarter. Stonepine Capital Management LLC acquired a new position in Vanda Pharmaceuticals during the third quarter worth $2,065,000. Finally, Los Angeles Capital Management LLC raised its stake in Vanda Pharmaceuticals by 42.2% during the third quarter. Los Angeles Capital Management LLC now owns 465,954 shares of the biopharmaceutical company’s stock worth $2,013,000 after acquiring an additional 138,284 shares in the last quarter. 88.14% of the stock is currently owned by institutional investors and hedge funds.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.